2-氯-4-氧-6-氟喹唑啉 | 769158-12-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 2-氯-4-氧-6-氟喹唑啉
• 中文别名: 2-氯-6-氟-4(1H)-喹唑啉酮
• 英文名称: 2-chloro-6-fluoroquinazolin-4(3H)-one
• 英文别名: 2-chloro-6-fluoro-3H-quinazolin-4-one
• CAS: 769158-12-5
• 化学式: C₈H₄ClFN₂O
• 分子量: 198.584
• InChiKey: CBHYEOLZQCLMSY-UHFFFAOYSA-N

物化性质

• 沸点：
  339.8±44.0 °C(Predicted)
• 密度：
  1.61±0.1 g/cm3 (20 ºC 760 Torr)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  41.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933990090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Chloro-6-fluoroquinazolin-4(3h)-one
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Chloro-6-fluoroquinazolin-4(3h)-one
CAS number: 769158-12-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H4ClFN2O
Molecular weight: 198.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氯-4-氧-6-氟喹唑啉 在 碳酸氢钠 、 potassium carbonate 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成 2-({2-[(3R)-3-aminopiperidin-1-yl]-6-fluoro-4-oxo-3,4-dihydroquinazolin-3-yl}methyl)benzonitrile
  参考文献：
  名称：

  阿格列汀的发现：二肽基肽酶IV的有效，选择性，生物利用度和有效抑制剂。

  摘要：

  阿格列汀是一种有效的，选择性的丝氨酸蛋白酶二肽基肽酶IV（DPP-4）抑制剂。在本文中，我们描述了基于阿格列汀和相关喹唑啉酮的DPP-4抑制剂的结构设计和优化。口服后，这些非共价抑制剂可在糖尿病动物模型中持续降低血浆DPP-4活性并降低血糖。阿格列汀目前正在2型糖尿病患者中进行III期试验。

  DOI：

  10.1021/jm070104l
• 作为产物：
  描述：

  2-氨基-5-氟苯甲酸 在 sodium hydroxide 、 N,N-二甲基苯胺 、 三氯氧磷 作用下， 以 四氢呋喃 为溶剂， 反应 20.0h， 生成 2-氯-4-氧-6-氟喹唑啉
  参考文献：
  名称：

  阿格列汀的发现：二肽基肽酶IV的有效，选择性，生物利用度和有效抑制剂。

  摘要：

  阿格列汀是一种有效的，选择性的丝氨酸蛋白酶二肽基肽酶IV（DPP-4）抑制剂。在本文中，我们描述了基于阿格列汀和相关喹唑啉酮的DPP-4抑制剂的结构设计和优化。口服后，这些非共价抑制剂可在糖尿病动物模型中持续降低血浆DPP-4活性并降低血糖。阿格列汀目前正在2型糖尿病患者中进行III期试验。

  DOI：

  10.1021/jm070104l

文献信息

• 八氢吡咯并[3,4-c]吡咯衍生物及其使用方法 和用途
  申请人：广东东阳光药业有限公司

  公开号：CN105949203B

  公开（公告）日：2018-07-13

  本发明涉及八氢吡咯并[3,4‑c]吡咯衍生物及其使用方法和用途。本发明所述的化合物以及包含该化合物的药物组合物用于拮抗食欲素受体。本发明还涉及制备这类化合物和药物组合物的方法，以及它们在治疗或预防与食欲素受体相关疾病中的用途。
• [EN] PIPERAZINE DERIVATIVES AS MAGL INHIBITORS<br/>[FR] DÉRIVÉS DE PIPÉRAZINE UTILISÉS EN TANT QU'INHIBITEURS DE MAGL
  申请人：HOFFMANN LA ROCHE

  公开号：WO2019072785A1

  公开（公告）日：2019-04-18

  The invention provides new heterocyclic compounds having general Formula (I), or a pharmaceutically acceptable salt thereof, wherein R1, R2, X, Y1 and Y2 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

  这项发明提供了具有一般式（I）的新的杂环化合物，或其药用可接受的盐，其中R1、R2、X、Y1和Y2如本文所述，包括这些化合物的组合物，制造这些化合物的方法以及使用这些化合物的方法。
• Bifunctional Hydrogen-Bond Donors That Bear a Quinazoline or Benzothiadiazine Skeleton for Asymmetric Organocatalysis
  作者：Tsubasa Inokuma、Masaya Furukawa、Takuya Uno、Yusuke Suzuki、Kohzo Yoshida、Yoshiaki Yano、Katsumi Matsuzaki、Yoshiji Takemoto

  DOI：10.1002/chem.201101338

  日期：2011.9.5

  (HB)‐donor catalysts that bear a 2‐aminoquinazolin‐4‐(1H)‐one or a 3‐aminobenzothiadiazine‐1,1‐dioxide skeleton have been developed, and it has been shown that these catalyst motifs act similarly to other HB‐donor catalysts such as thioureas. The highly enantioselective hydrazination of 1,3‐dicarbonyl compounds was realized even at room temperature with up to 96 % ee for 2‐aminoquinazolin‐4‐(1H)‐one‐type

  已开发出带有2-氨基喹唑啉-4-（1 H）-one或3-氨基苯并噻二嗪-1,1-二氧化物骨架的氢键（HB）供体催化剂，并且已证明这些催化剂基序起作用与其他HB-施主催化剂（如硫脲）相似。1,3-二羰基化合物的高度对映选择性肼化反应即使在室温下也能达到2-氨基喹唑啉-4-（1 H）的96％  ee一类催化剂，比相应的尿素和硫脲催化剂更有效。此外，苯并噻二嗪-1,1-二氧化物型催化剂还显示出可以以高对映选择性促进炔酸酯向烯丙酸酯的异构化。为克服产物以与起始炔酸酯的混合物形式获得的问题，我们开发了炔酸酯的串联异构化和环加成反应，以合成高级手性化合物，如双环[2.2.1]庚烯和3-亚烷基吡咯烷，而不会造成重大损失对映选择性。
• [EN] SUBSTITUTED QUINAZOLINE COMPOUNDS AND PREPARATION AND USES THEREOF<br/>[FR] COMPOSÉS DE QUINAZOLINE SUBSTITUÉS, AINSI QUE PRÉPARATION ET UTILISATIONS DE CEUX-CI
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2017012502A1

  公开（公告）日：2017-01-26

  The present invention relates quinazolinone compounds of Formula (I), as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses； wherein the compounds or pharmaceutical compositions disclosed herein can be used for antagonizing the orexin receptor. The present invention also relates to uses of the compounds or pharmaceutical compositions in treating or preventing neurological and psychiatric disorders and diseases of the central nervous system in mammals, especially in humans.

  本发明涉及Formula (I)的喹唑啉酮化合物，以及它们的制备和用途，并进一步涉及包含这些化合物的药物组合物及其用途；本文所披露的化合物或药物组合物可用于拮抗促觉醒荷尔蒙受体。本发明还涉及这些化合物或药物组合物在治疗或预防哺乳动物，特别是人类中枢神经系统的神经和精神障碍和疾病中的用途。
• Iridium-Catalyzed Enantioselective Synthesis of Dihydroimidazoquinazolinones by Elaborate Tuning of Chiral Cyclic Ligands
  作者：Fei Peng、Hua Tian、Pengxiang Zhang、Can Liu、Xudong Wu、Xi Yuan、Haijun Yang、Hua Fu

  DOI：10.1021/acs.orglett.7b03230

  日期：2017.12.1

  prepared in high yields and enantiomeric excess. The allylation was performed under catalysis of iridium-chiral cyclic phosphoramidite complexes, in which the reactivity and enantioselectivity of the substrates were elaborately tuned by our developed chiral cyclic phosphoramidite ligands with adjustable sizes of rings.

  （E）-4-（烷基（4-氧代-3,4-二氢喹唑啉-2-基）氨基）丁-2-烯-1-基甲基碳酸酯的高效，对映选择性分子内烯丙基化反应得到了开发，并且相应的高产率和对映体过量制备了二氢咪唑并喹唑啉酮。烯丙基化是在铱-手性环状亚磷酰胺络合物的催化下进行的，其中我们开发的具有可调环尺寸的手性环状亚磷酰胺配体精心调节了底物的反应性和对映选择性。